An interventional study of Blood and bone marrow sample in Leukemia,Myeloid, Chronic, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 17 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-27.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France — 15 open to participants now, 24 under way, 4 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France.
Among the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France, this one is the 19th largest by planned enrollment of the 83 interventional ones that give a count, is one of 4 that started in 2023, is one of 9 with no phase, reaches primary completion later than 6 of the 23 other live ones, and was the 97th registered.
895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →15 of the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, Australia and 14 more countries
Ages 1–18
Novartis Pharmaceuticals · Sites in France
Ages 18–99
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Sites in France, United States, Australia and 6 more countries
Ages 18+
Ascentage Pharma Group Inc. · Sites in France, United States, Australia and 13 more countries
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 6–18
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 42 · Phase 3 21 · Phase 4 5
First in 1999; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 321 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 150 across the 83 interventional studies, 200 across the 19 observational. Of the 74 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 103 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 3 studies filed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive — fewer than ten, so there is no comparison to draw.
3 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423911Phase 3Ascentage Pharma Group Inc.Study of Olverembatinib (HQP1351) in Patients With CML-CP | 2027-06-30 |
| NCT06092879Novartis PharmaceuticalsAsciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France | 2026-12-15 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 103 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Blood and bone marrow sample
Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12. An optional bone marrow sample will be taken during the myelogram performed at diagnosis. Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36
Biological age determination
The difference between biological age and chronological age (of the clone and the patient) expressed as a difference and as a percentage.
Time frame: Day 0;Month 3;Month 12
Individual fragility assessment
Individual fragility assessed by Geriatric Core Data set assessing social status, independence at home, mobility, nutrition, cognitive status, mood and comorbidities.
Time frame: Day 0;Month 6;Month 12;Month 24;Month 36
Individual fragility assessment
Individual fragility assessed by Rockwood clinical frailty score ranging from 1 (very fit) to 9 (at the end of life)
Time frame: Day 0;Month 6;Month 12;Month 24;Month 36
Tolerance of tyrosine kinase inhibitors
Tolerance assessed by actual dose received
Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36
Tolerance of tyrosine kinase inhibitors
Tolerance assessed by the number of tyrosine kinase inhibitor discontinuation due to intolerance
Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36
Tolerance of tyrosine kinase inhibitors
Tolerance assessed by a description of adverse events as assessed by CTCAE v5.0
Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36
Tolerance of tyrosine kinase inhibitors
Tolerance assessed by changes and number of tyrosine kinase inhibitor lines
Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36
Tolerance of tyrosine kinase inhibitors
Tolerance assessed by a description of treatment sequences
Time frame: Day 0;Month 3;Month 6;Month 12;Month 24;Month 36
Distribution of individual clinical fragility levels assessed by Geriatric Core Data set at the time of diagnosis.
Individual fragility assessed by Geriatric Core Data set assessing social status, independence at home, mobility, nutrition, cognitive status, mood and comorbidities at the time of diagnosis.
Time frame: Day 0
Distribution of individual clinical fragility levels assessed by Rockwood clinical frailty score at the time of diagnosis.
Individual fragility assessed by Rockwood clinical frailty score ranging from 1 (very fit) to 9 (at the end of life) at the time of diagnosis.
Time frame: Day 0
Evaluation of therapeutic response through quantification of the BCR::ABL transcript
Quantification of BCR::ABL transcript expressed as copy number relative to 100 copies of control gene transcripts
Time frame: Month 3;Month 6;Month 12;Month 15;Month 18;Month 21;Month 24;Month 27;Month 30;Month 33;Month 36
Assessment of therapeutic response by quantification of residual disease
Decrease in residual disease and achievement of MMR (≤0.1%), MR4 (≤0.01%), MR4.5 (≤0.032%), MR5 (≤0.001%) thresholds)
Time frame: Month 3;Month 6;Month 12;Month 15;Month 18;Month 21;Month 24;Month 27;Month 30;Month 33;Month 36
Assessment of patients' quality of life
Quality of life assessed using the European Organisation for Research and Treatment of Cancer LG Core Questionnaire (EORTC QLQ-C30) is a 30-item instrument designed to measure quality of life in all cancer patients, with a higher score indicating a better health-related quality of life
Time frame: Day 0;Month 6;Month 12;Month 24;Month 36
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Nov 2025, 24 months after the start.
Of 25 interventional studies with no phase under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 123. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →
University Hospital, Clermont-Ferrand →